Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172134 | 0.94 | CYP2C9 (0.61) | CYP2C9HIF1ACYP2D6MEN1KMT2A | |
| Fluoride SCHEMBL9125458 | 0.91 | CYP2C9 (0.59) | CYP2C9HIF1ACYP2D6MEN1KMT2A | |
| SCHEMBL14166678 | 0.88 | CYP2C9 (0.64) | CYP2C9HIF1ACYP2D6MEN1KMT2A | |
| Bromomethane SCHEMBL3169377 | 0.81 | CYP2C9 (0.57) | CYP2C9HIF1ACYP2D6MEN1KMT2A | |
| Benzylic Acid SCHEMBL4823051 | 0.80 | CYP2C9 (0.65) | CYP2C9HIF1ACYP2D6MEN1KMT2A | |
| Bromomethane SCHEMBL208552 | 0.79 | CYP2C9 (0.55) | CYP2C9HIF1ACYP2D6MEN1KMT2A | |
| Bromomethane SCHEMBL3163413 | 0.79 | CYP2C9 (0.55) | CYP2C9HIF1ACYP2D6TSHRCYP1A2 | |
| Bromomethane SCHEMBL3163376 | 0.79 | CYP2C9 (0.50) | CYP2C9HIF1ACYP2D6KMT2ATSHR | |
| SCHEMBL1625391 | 0.78 | MEN1 (0.54) | CYP2C9HIF1ACYP2D6MEN1KMT2A | |
| Bromomethane SCHEMBL3169191 | 0.78 | CYP2C9 (0.46) | CYP2C9HIF1ACYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652138-B2 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-26 | — | — | US | claimed |
| US-8420666-B2 | Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | disclosed |
| US-20120004201-A1 | PHOSPHODIESTARASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| EP-2346867-A1 | PHOSPHODIESTARASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2011-07-27 | — | — | EP | disclosed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100272638-A1 | RADIOLABELLED MICROPARTICLES, PROCESSES FOR THE PREPARATION THEREOF AND THE USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| WO-2010046791-A1 | PHOSPHODIESTARASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-04-29 | — | — | WO | disclosed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045980-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
| US-7071706-B2 | Measuring device for rapid non-destructive measurement of the contents of capsules | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2006-07-04 | — | — | US | disclosed |
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6951888-B2 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-04 | — | — | US | disclosed |
| US-20050154555-A1 | Measuring device for rapid non-destructive measurement of the contents of capsules | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6852728-B2 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-08 | — | — | US | disclosed |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004201-A1 | PHOSPHODIESTARASE INHIBITORS | PDE4A, PDE7A, PDE4B | CYP2C9 2226/4885HIF1A 2916/4885CYP2D6 1727/4885 |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4A, PDE3A | CYP2C9 781/4885HIF1A 2997/4885CYP2D6 787/4885 |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | CHRM1, CHRM3, CHRM2 | CYP2C9 368/4885HIF1A 3172/4885CYP2D6 162/4885 |
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | CHRM1, CHRM2, ADRB1 | CYP2C9 297/4885HIF1A 1034/4885CYP2D6 157/4885 |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | ADRA2C, ADRA1D, ADRB1 | CYP2C9 453/4885HIF1A 1246/4885CYP2D6 252/4885 |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | CHRM1, CHRM3, CHRM2 | CYP2C9 162/4885HIF1A 3108/4885CYP2D6 147/4885 |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | CYP2C9 644/4885HIF1A 2792/4885CYP2D6 590/4885 |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | CYP2C9 655/4885HIF1A 2872/4885CYP2D6 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.